Vancomycin

Generic Name
Vancomycin
Brand Names
Firvanq, Vancocin
Drug Type
Small Molecule
Chemical Formula
C66H75Cl2N9O24
CAS Number
1404-90-6
Unique Ingredient Identifier
6Q205EH1VU
Background

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...

Indication

Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...

Associated Conditions
Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Associated Therapies
-
Clinical Trials
Related News

Daptomycin or Vancomycin in Treating Bacteria in the Blood in Patients With Neutropenia Caused By Chemotherapy

First Posted Date
2006-02-24
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Registration Number
NCT00296049
Locations
🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas

Phase 4
Completed
Conditions
Cellulitis
First Posted Date
2006-02-23
Last Posted Date
2017-09-07
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
80
Registration Number
NCT00295178
Locations
🇺🇸

Joseph Still Research Foundation, Augusta, Georgia, United States

Pharmacokinetics of Vancomycin in Adults Receiving ECMO

Phase 4
Completed
Conditions
Extracorporeal Membrane Oxygenation
First Posted Date
2006-01-24
Last Posted Date
2012-12-06
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
24
Registration Number
NCT00281281
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

First Posted Date
2005-12-23
Last Posted Date
2019-10-14
Lead Sponsor
Bausch Health Americas, Inc.
Target Recruit Count
237
Registration Number
NCT00269399
Locations
🇺🇸

Newland Medical Association, Southfield, Michigan, United States

🇺🇸

University of Maryland, Baltimore, Maryland, United States

🇺🇸

Digestive Health Specialists, PA, Tupelo, Mississippi, United States

and more 60 locations

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

First Posted Date
2005-09-29
Last Posted Date
2012-07-26
Lead Sponsor
Basilea Pharmaceutica
Target Recruit Count
784
Registration Number
NCT00228982

Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus

Not Applicable
Completed
Conditions
Staphylococcal Infections
First Posted Date
2005-09-15
Last Posted Date
2008-06-20
Lead Sponsor
University of British Columbia
Target Recruit Count
60
Registration Number
NCT00175370
Locations
🇨🇦

Vancouver General Hospital Intensive Care Unit, Vancouver, British Columbia, Canada

Prevention of Gastrostomy-Related Wound Infection by Vancomycin in Carriers of Methicillin-Resistant Staphylococcus Aureus.

Phase 2
Conditions
Wound Infection
First Posted Date
2005-09-08
Last Posted Date
2005-12-29
Lead Sponsor
University Hospital, Geneva
Target Recruit Count
96
Registration Number
NCT00150852
Locations
🇨🇭

Division of Gastroenterology, University Hospital, Geneva, Switzerland

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud, Switzerland

🇫🇷

Centre Hospitalier Universitaire (CHU), Grenoble, France

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Phase 3
Completed
Conditions
Bacterial Pneumonia
Interventions
Drug: Vancomycin
Drug: Telavancin
First Posted Date
2005-07-26
Last Posted Date
2019-01-16
Lead Sponsor
Cumberland Pharmaceuticals
Target Recruit Count
771
Registration Number
NCT00124020
Locations
🇮🇱

Sheba Medical Center, Infectious Disease Unit, Tel Hashomer, Israel

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

Phase 3
Completed
Conditions
Bacterial Pneumonia
Interventions
Drug: Telavancin
Drug: Vancomycin
First Posted Date
2005-04-12
Last Posted Date
2019-01-16
Lead Sponsor
Cumberland Pharmaceuticals
Target Recruit Count
761
Registration Number
NCT00107952
Locations
🇺🇸

Baystate Medical Center, Springfield, Massachusetts, United States

Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus

First Posted Date
2005-04-12
Last Posted Date
2019-01-16
Lead Sponsor
Cumberland Pharmaceuticals
Target Recruit Count
1035
Registration Number
NCT00107978
Locations
🇺🇸

Louisiana State University Health Sciences Center, Dept of Med/ER Med, New Orleans, Louisiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy